Quick Answer
Esperion Therapeutics, Inc. reported Long-Term Debt of $1.02 million for fiscal year 2016.
Esperion Therapeutics, Inc. Long-Term Debt — Annual History
| Fiscal Year | Long-Term Debt | YoY Change |
|---|---|---|
| 2016 | $1.02M | -62.0% |
| 2015 | $2.69M | -36.5% |
| 2014 | $4.23M | -43.8% |
| 2012 | $7.53M | — |
Quarterly Long-Term Debt
| Quarter Ending | Long-Term Debt | YoY | QoQ |
|---|---|---|---|
| June 30, 2017 | $140.0K | -92.5% | -76.1% |
| March 31, 2017 | $585.0K | -74.4% | -42.8% |
| December 31, 2016 | $1.02M | -62.0% | -29.6% |
| September 30, 2016 | $1.45M | -53.0% | -22.4% |
| June 30, 2016 | $1.87M | -46.1% | -18.0% |
| March 31, 2016 | $2.28M | -40.8% | -15.1% |
| December 31, 2015 | $2.69M | -36.5% | -12.8% |
| September 30, 2015 | $3.08M | -34.0% | -11.2% |
- Esperion Therapeutics, Inc. showed a decrease of -62.0% in Long-Term Debt compared to the prior fiscal year.
- Over the 2012–2016 period, Esperion Therapeutics, Inc.’s long-term debt has declined by 86.4% (from $7.53 million to $1.02 million).
- The most recent figure is from Esperion Therapeutics, Inc.’s fiscal year 2017 report (Form 10-K), filed with the SEC on February 20, 2018.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: